Cross-Sector entity
ip-patent is the sole category represented across all 1 tracked stories. Recce Pharmaceuticals Ltd is most often covered alongside ANVISA, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Recce Pharmaceuticals Ltd, all published on March 24, 2026.
1 verified story tracked
Last mentioned: Mar 24, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
ip-patent is the sole category represented across all 1 tracked stories. Recce Pharmaceuticals Ltd is most often covered alongside ANVISA, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Recce Pharmaceuticals Ltd, all published on March 24, 2026.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Recce Pharmaceuticals Ltd. Shared-story counts are live from our verified record — not editorial picks.
Brazil Patent Grant
Recce Pharmaceuticals officially receives patent grant from the Brazilian National Institute of Industrial Property (INPI).
Clinical Expansion
Recce expands Phase II clinical trials for RECCE® 327 in topical and intravenous applications.
US Patent Milestone
Recce secures key composition of matter patents in the United States, strengthening its North American position.
Recce Pharmaceuticals has been granted a critical patent in Brazil for its synthetic anti-infective platform, marking a significant expansion into South America's largest healthcare market. The patent protects the composition and manufacturing of its lead candidates, RECCE® 327 and RECCE® 529, as the company targets the global antimicrobial resistance crisis.
Source: proactiveinvestors.com · finance.yahoo.com
